^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Small Lymphocytic Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Preferred regimens…Idelalisib + rituximab
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Lymphocytic Leukemia)
    New
    Excerpt:
    Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)...as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.